Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
6.07
+0.45 (8.01%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 279 employees as of December 31, 2024. The number of employees decreased by 46 or -14.15% compared to the previous year.
Employees
279
Change (1Y)
-46
Growth (1Y)
-14.15%
Revenue / Employee
$520,563
Profits / Employee
-$273,914
Market Cap
52.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
KPTI News
- 27 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC - PRNewsWire
- 2 months ago - Karyopharm Announces 1-for-15 Reverse Stock Split - PRNewsWire
- 2 months ago - Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress - PRNewsWire
- 2 months ago - Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region - PRNewsWire
- 2 months ago - Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 - PRNewsWire
- 3 months ago - Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives - PRNewsWire